Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve biomedical rese ...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES THE SHELF PROSPECTUS SUPPLEMENT, THE CORRESPONDING BASE SHELF PROSPECTUS AND ANY AMENDMENT TO THE DOCUMENTS ARE ACCESSIBLE THROUGH SEDAR+ OR WILL BE ACCESSIBLE THROUGH SEDAR+ WITHIN 2 BUSINESS DAYS, AS APPLICABLE TORONTO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Andean Precious Metals Corp. (“Andean” or the “Company”) (TSX: APM) (OTCQX: ANPMF) is pleased to announce that it has entered into an agreement with PMB Partners LP (t ...

Core Insights - DiamiR Biosciences Corp. and Aptorum Group Limited are set to present at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, showcasing innovative blood-based diagnostic tests for brain health and neurodegeneration [1][4] Presentation Details - The presentations will occur on December 3, 2025, at the Hilton San Diego Bayfront, focusing on microRNA classifiers and their role in classifying cognitive impairment stages [2] - Poster 225 will discuss developing microRNA classifiers enriched in brain and inflammation in plasma samples, in collaboration with New York University [2] - Poster 240 will characterize stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs, in collaboration with the University of Pennsylvania [3] Merger Information - Aptorum Group and DiamiR have entered into a definitive agreement for an all-stock merger, with DiamiR becoming a wholly-owned subsidiary of Aptorum upon completion, expected in Q1 2026 [5] - The merger is subject to stockholder approval and customary closing conditions [5] Company Profiles - Aptorum Group is a clinical stage biopharmaceutical company focused on developing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [6] - DiamiR Biosciences specializes in developing minimally invasive tests for early detection and monitoring of brain health conditions, supported by over 50 issued patents [8]

Registration No. [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTORUM GROUP LIMITED (Exact Name of Registrant as Specified in its Charter) Cayman Islands 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) 17 Hanover Square London W1S 1BN, United Kingdom Telephone: +44 20 80929299 (Address, ...

Group 1 - The article highlights significant declines in the stock prices of several Chinese concept stocks, with Dreamland experiencing the largest drop of 80.98% [1] - Other notable declines include Tianruixiang at 46.5%, Zhiling Group at 29.96%, and Mercurity Fintech at 26.69% [1] - The trading volumes for these stocks varied, with Dreamland having a transaction amount of 37.5017 million and Mercurity Fintech at 8.0682 million [1] Group 2 - Dreamland's latest price is reported at 1.160, down by 4.940 [1] - Tianruixiang's latest price is 1.260, down by 1.095 [1] - Zhiling Group's latest price is 1.660, down by 0.710 [1]

Core Viewpoint - Aptorum Group Limited has announced a registered direct offering of 1,000,000 Class A ordinary shares at a price of $2.00 per share, with potential additional gross proceeds of up to $4 million from unregistered warrants [1][3]. Group 1: Offering Details - The offering is expected to generate gross proceeds of $2 million before deducting fees and expenses [3]. - The company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of $2.00 per share, which will be exercisable upon issuance and expire in twenty-four months [1][3]. - The closing of the offering is anticipated to occur around October 14, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund expenses related to the merger agreement between Aptorum and DiamiR Biosciences Corp., as well as for general working capital for both companies pending the merger's closing [3]. Group 3: Regulatory Information - The ordinary shares are being offered under a "shelf" registration statement that was declared effective by the SEC on January 19, 2023 [4]. - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act and have not been registered under applicable securities laws [5].

Core Viewpoint - Aptorum Group Limited announces the addition of Dr. Laura A. Philips to its board of directors following the merger with DiamiR Biosciences Corp, aiming to enhance its strategic initiatives in addressing aging-related diseases [1][3]. Company Overview - Aptorum Group is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs, particularly in oncology and infectious diseases [8]. - DiamiR Biosciences is a private molecular diagnostics company that develops minimally invasive tests for early detection and monitoring of brain health conditions, utilizing a proprietary platform technology based on microRNA signatures [9]. Leadership Changes - Dr. Laura A. Philips, co-founder and CEO of Spheryx, Inc., joins Aptorum's board as an independent director, bringing extensive experience in life sciences and technology [2][3]. - Following the merger, Dr. Kira Sheinerman from DiamiR will join the combined board, and Dr. Alidad Mireskandari will assume the role of President and COO [4][5]. Strategic Goals - The merger is expected to strengthen market awareness and execution capabilities for both Aptorum and DiamiR, particularly in the development of tests for Alzheimer's and other brain diseases [3][4]. - The transaction is anticipated to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions [3].

Core Viewpoint - Chinese concept stocks experienced significant gains, with notable increases in share prices for several companies, indicating a positive market sentiment towards these stocks [1] Group 1: Top Gainers - Nature's Sunshine Products (UPC) saw a remarkable increase of 82.98%, closing at a price of 9.460, with a trading volume of 235 million [1] - Melco Resorts & Entertainment (MSC) rose by 19.23%, reaching a price of 4.680, with a trading volume of 48,500 [1] - I-Mab (IMAB) increased by 16.02%, closing at 5.070, with a trading volume of 29.76 million [1] - Zai Lab (APM) experienced a gain of 15.31%, closing at 2.410, with a trading volume of 1.6078 million [1] - China Natural Resources (CHNR) rose by 14.84%, closing at 5.700, with a trading volume of 8.8604 million [1]

Merger Agreement and Structure - Aptorum and DiamiR entered into a Merger Agreement on July 14, 2025, with DiamiR becoming a wholly owned subsidiary of Aptorum[65]. - Following the Merger, Aptorum shareholders are expected to own approximately 30% of the outstanding shares of the Combined Company, while DiamiR stockholders are expected to own approximately 70%[69]. - The proposed share consolidation will occur at a ratio of either 2-1, 3-1, or other ratios as determined by the Board[74]. - The Domestication Proposal requires a special resolution with at least two-thirds of the votes cast by Aptorum Class A and Class B shareholders[73]. - The issuance of shares of Aptorum Delaware common stock to DiamiR stockholders will represent more than 20% of the shares outstanding immediately prior to such issuance[77]. - Aptorum plans to change its corporate name to "Niki BioSolutions, Inc." following the Merger[65]. - The approval of the Domestication Proposal is a condition to closing the Merger under the Merger Agreement[73]. - A new stock incentive plan will be implemented with an unspecified number of shares of Common Stock[77]. - Five directors have been proposed for appointment to the Combined Company, effective upon the Closing of the Merger[77]. - The Combined Company board will consist of five members, with three designated by Aptorum and two by DiamiR, including Ian Huen as Chair[88]. - The executive management team post-Merger will include Ian Huen as CEO, Gary Anthony as CFO, and Alidad Mireskandari as President and COO[89]. - The merger agreement includes provisions for DiamiR stockholders to appoint directors to the Combined Company's board, contingent on their ownership percentage[140]. Financial Overview - DiamiR has incurred net losses of $743,235 and $614,405 for the years ended May 31, 2025 and 2024, respectively, with an accumulated deficit of $5,822,571[128]. - DiamiR has raised over $9.7 million in grant funding, including approximately $3.86 million from the NIH for the development of its lead diagnostic product, CogniMIR®[130]. - DiamiR has not generated any revenues from product sales and expects to continue incurring net losses and negative cash flows for the foreseeable future[128]. - DiamiR's valuation at the time of the merger closing is set at $18.7 million, with Aptorum's stock price at $0.94 per share prior to the merger agreement[151]. - The combined company will maintain a cash balance of no less than $2,260,000 and working capital of no less than $1,644,000 at closing, with Aptorum currently holding approximately $2.8 million in cash[174]. - Aptorum has approximately $2.8 million in cash and current assets of approximately $3.0 million as of June 30, 2025, with a target to maintain at least $2,260,000 in unrestricted cash at the closing of the Merger[190]. Strategic Focus and Operations - Aptorum focuses on R&D and has streamlined operations by terminating clinical services and suspending non-lead R&D projects to enhance shareholder value[125]. - Aptorum aims to develop a broad range of therapeutics and diagnostics, focusing on unmet medical needs in oncology and infectious diseases[121]. - The company is actively seeking strategic collaborators to provide financial support and clinical expertise for advancing its therapeutic programs[123]. - Aptorum's lead projects include ALS-4 and SACT-1, with ALS-4 progressing towards IND submission after positive FDA feedback[123]. - The merger is expected to create long-term value through DiamiR's product candidates in brain health, cancer, and inflammatory diseases[153]. - The merger is seen as more favorable than potential alternatives, which could lead to a delisting of Aptorum's Class A ordinary shares from Nasdaq[152]. Regulatory and Approval Considerations - The merger is subject to various conditions, including the approval of the Nasdaq Stock Issuance Proposal and the effectiveness of a registration statement on Form S-4[172]. - The completion of the Merger is subject to regulatory approvals which may delay or prevent consummation[185]. - The Merger will be accounted for under GAAP, with Aptorum as the accounting acquirer and DiamiR as the accounting acquiree[181]. - The time required to obtain approval from regulatory authorities like the FDA and EMA is unpredictable and typically takes many years[244]. - Regulatory authorities may require additional studies or data, delaying approval and commercialization plans for Aptorum's drug candidates[247]. Risks and Challenges - The market price of the Combined Company's shares may decline due to ownership dilution and failure to achieve anticipated benefits from the Merger[196]. - The Combined Company may face significant management challenges and resource allocation issues during the integration process post-Merger[198]. - The company currently does not generate revenue from product sales and may never become profitable without raising additional capital[217]. - The average cost of launching a new drug is estimated to approach $2.6 billion and can take around 12 years to reach the market[221]. - Approximately 86.2% of drug candidates entering phase 1 trials fail to achieve drug approval[221]. - The company has limited financial and managerial resources, focusing on three Lead Projects, which may ultimately prove unsuccessful[227]. - Delays in patient enrollment for clinical trials could result in increased costs and affect the timing or outcome of the trials[233]. - Compliance with current Good Clinical Practices (cGCP) is essential, and failure to comply may render clinical data unreliable[238]. - Clinical trials may be suspended or terminated due to safety issues or non-compliance with regulatory requirements[246]. - Significant clinical trial delays could allow competitors to bring products to market before Aptorum, impairing its commercialization efforts[243]. Management and Governance - Certain officers and directors of Aptorum and DiamiR have interests in the Merger that may differ from those of shareholders, potentially influencing their support for the Merger[194]. - No independent fairness opinion was obtained regarding the Merger, with the consideration reached through negotiations deemed fair by Aptorum's board[195]. - Anti-takeover provisions in the Proposed Charter and Bylaws could make it difficult for stockholders to replace management or initiate beneficial transactions[209]. - The Proposed Charter will designate Delaware courts as the exclusive forum for certain litigation, potentially limiting stockholders' options for judicial recourse[213].